UTHR
United Therapeutics Corporation
NASDAQ: UTHR · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$571.07
+0.34% today
Updated 2026-04-29
Market cap
$25.03B
P/E ratio
20.48
P/S ratio
7.86x
EPS (TTM)
$27.89
Dividend yield
—
52W range
$272 – $608
Volume
0.6M
United Therapeutics Corporation (UTHR) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
2 of 8
Last 8 quarters
Avg EPS surprise
-1.7%
Last 4 quarters
Revenue YoY growth
+7.4%
Most recent quarter
EPS YoY growth
+24.4%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+3.4%
Last 3 reports
Positive reaction rate
67%
2 of 3 quarters
Largest single-day move
+9.2%
2025-10-29
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-02-25 | $7.70 | +8.5% | $473.43 | $503.60 | +6.4% |
| 2025-10-29 | $7.16 | -2.2% | $415.34 | $453.53 | +9.2% |
| 2025-07-29 | $6.41 | -12.8% | $298.14 | $281.95 | -5.4% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $7.10 | $7.70 | +8.5% | $790.20M | +7.4% |
| 2025-09-30 | $7.32 | $7.16 | -2.2% | $799.50M | +6.8% |
| 2025-06-30 | $7.35 | $6.41 | -12.8% | $798.60M | +11.7% |
| 2025-03-31 | $6.66 | $6.63 | -0.5% | $794.40M | +17.2% |
| 2024-12-31 | $6.27 | $6.19 | -1.2% | $735.90M | +19.7% |
| 2024-09-30 | $6.43 | $6.39 | -0.6% | $748.90M | +22.9% |
| 2024-06-30 | $6.40 | $5.85 | -8.6% | $714.90M | +19.8% |
| 2024-03-31 | $5.65 | $6.17 | +9.2% | $677.70M | — |
| 2023-12-31 | $4.19 | $4.36 | +4.1% | $614.70M | — |
| 2023-09-30 | $5.04 | $5.38 | +6.7% | $609.40M | — |
| 2023-06-30 | $4.51 | $5.24 | +16.2% | $596.50M | — |
Analyst EPS and revenue estimates for upcoming years
| Period | EPS estimate | Revenue estimate | Revenue growth | Analysts | Confidence |
|---|---|---|---|---|---|
| 2026 (E) | $29.87 | $3.4B | +7.3% | 14 | high |
| 2027 (E) | $33.42 | $3.9B | +13.2% | 14 | high |
| 2029 (E) | $45.20 | $5.2B | +16.5% | 14 | medium |
| 2030 (E) | $53.10 | $6.0B | +17.5% | 14 | medium |
Frequently asked questions
Has United Therapeutics Corporation beaten earnings estimates?
United Therapeutics Corporation has beaten Wall Street EPS estimates in 2 of its last 8 quarterly reports, with an average EPS surprise of -1.7% over the last 4 quarters.
How does UTHR stock react to earnings?
UTHR stock has moved an average of +3.4% in the trading day following earnings over its last 3 reports, with positive reactions in 67% of those quarters.
What is United Therapeutics Corporation's revenue growth rate?
United Therapeutics Corporation reported year-over-year revenue growth of +7.4% in its most recent quarter, with EPS growing +24.4% year-over-year.
What is the expected EPS for UTHR in 2026?
Analysts expect United Therapeutics Corporation to report EPS of $29.87 for fiscal year 2026, on revenue of $3.4B, based on estimates from 14 analysts.